Asia Pacific Monoclonal Antibodies Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)


No. of Pages: 168    |    Report Code: TIPRE00028619    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Buy Now
Asia Pacific Monoclonal Antibodies Market

The Asia Pacific monoclonal antibodies market is expected to reach US$ 44,729.7 million by 2028 from US$ 18,344.5 million in 2021. The market is estimated to grow at a CAGR of 13.6% from 2021–2028.

Advancements in manufacturing technologies with packaging and delivery can lower mAB production costs and increase efficiency. For example, WHO policy guidelines play an important role in adopting new technologies and their integration in financing and procurement platforms. Therefore, novel technologies are expected to lower mAB development and manufacturing costs during the forecast period. For instance, the IAVI report states that many researchers are applying cost-effective technologies for optimizing HIV-specific bnmABs for increasing potency, thereby lowering the cost of the overall product. Additionally, recent technological advancements offer lucrative opportunities to quickly isolate, develop and produce therapeutic or preventative mABs as a complementary approach to vaccine development as part of preparing for or responding to current and future pandemic outbreaks. For example, incorporating technological advancements in the process of identifying, optimizing, and producing results in delivering more potent, lower-cost monoclonal antibody products. Together, such strategic actions are expected to make it possible to address the growing inequity to these products, saving or improving millions of lives in the process in the near future. Therefore, with the influx of advanced technology for the development of mABs, the mAB market will grow faster in the coming years. For example, as per the statistics released by Firestone, approx. 43% of mAB sales were intended to treat immune system diseases, while 35% were used for tumor therapy in 2015. The sales of mABs accounted for over half of the total sales of all biopharmaceutical products.

 

The supply chain disruptions, along with the massive demand for efficient treatments for the therapy of COVID-19, have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. COVID-19 pandemic has broadly affected that economies in the Asia Pacific region. Countries such as India, China, Japan, South Korea were adversely affected by the pandemic. The socio-economics were severely affected, rising in negative inflation, GDPs, and a surge in unemployment in the region. The pandemic has affected three main aspects of the global economy: production, supply chain, and firms and financial markets. Japan, China, South Korea, India, and Australia are the most affected countries due to the increasing number of COVID-19 cases and the associated deaths. Manufacturers and suppliers of pharmaceuticals shift their focus from regular OTC and prescription drugs to developing and supplying COVID-19 essentials and medical devices used for respiratory issues. This scenario negatively impacts the monoclonal antibody. This pandemic is affecting the business operation of the various key players operating in this region.

 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The Asia Pacific monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.

 

Asia Pacific Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report

Asia Pacific Monoclonal Antibodies Strategic Insights

Strategic insights for the Asia Pacific Monoclonal Antibodies provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/asia-pacific-monoclonal-antibodies-market-strategic-framework.webp
Get more information on this report

Asia Pacific Monoclonal Antibodies Report Scope

Report Attribute Details
Market size in 2021 US$ 18,344.5 Million
Market Size by 2028 US$ 44,729.7 Million
Global CAGR (2021 - 2028) 13.6%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Source
  • Human
  • Humanized
  • Chimeric
  • Murine
By Production Method
  • In-Vitro
  • In-Vivo
By Indication
  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Inflammatory Diseases
  • Microbial Diseases
By Application
  • Therapeutic Applications
  • Diagnostic Applications
  • Research Applications
By End-User
  • Hospitals
  • Research Institutes
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Amgen Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Eli Lilly and Company
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Get more information on this report

    Asia Pacific Monoclonal Antibodies Regional Insights

    The geographic scope of the Asia Pacific Monoclonal Antibodies refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/asia-pacific-monoclonal-antibodies-market-geography.webp
    Get more information on this report

    Asia Pacific Monoclonal Antibodies Market Segmentation          

    By Source

    • Human
    • Humanized
    • Chimeric
    • Murine 

    By Production Method

    • In-Vitro
    • In-Vivo

    By Indication

    • Cancer
    • Autoimmune Diseases
    • Infectious Diseases
    • Inflammatory Diseases
    • Microbial Diseases
    • Others

    By Application

    • Therapeutic Applications
    • Diagnostic Applications
    • Research Applications

    By End-User

    • Hospitals
    • Research Institutes
    • Others

    By Country

    • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific

    Companies Mentioned

    • Novartis AG
    • Pfizer Inc.
    • GlaxoSmithKline plc.
    • Amgen Inc
    • DAIICHI SANKYO COMPANY, LIMITED
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca
    • Eli Lilly and Company
    • Bayer AG
    • Bristol-Myers Squibb Company

    The List of Companies - Asia Pacific Monoclonal Antibodies Market

    1. Novartis AG
    2. Pfizer Inc.
    3. GlaxoSmithKline plc.
    4. Amgen Inc
    5. DAIICHI SANKYO COMPANY, LIMITED
    6. F. Hoffmann-La Roche Ltd.
    7. AstraZeneca
    8. Eli Lilly and Company
    9. Bayer AG
    10. Bristol-Myers Squibb Company
    Frequently Asked Questions
    How big is the Asia Pacific Monoclonal Antibodies Market?

    The Asia Pacific Monoclonal Antibodies Market is valued at US$ 18,344.5 Million in 2021, it is projected to reach US$ 44,729.7 Million by 2028.

    What is the CAGR for Asia Pacific Monoclonal Antibodies Market by (2021 - 2028)?

    As per our report Asia Pacific Monoclonal Antibodies Market, the market size is valued at US$ 18,344.5 Million in 2021, projecting it to reach US$ 44,729.7 Million by 2028. This translates to a CAGR of approximately 13.6% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Monoclonal Antibodies Market report typically cover these key segments-

    • Source (Human, Humanized, Chimeric, Murine)
    • Production Method (In-Vitro, In-Vivo)
    • Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases)
    • Application (Therapeutic Applications, Diagnostic Applications, Research Applications)
    • End-User (Hospitals, Research Institutes)

    What is the historic period, base year, and forecast period taken for Asia Pacific Monoclonal Antibodies Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Monoclonal Antibodies Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Monoclonal Antibodies Market?

    The Asia Pacific Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Amgen Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Eli Lilly and Company
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Who should buy this report?

    The Asia Pacific Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.